Загрузка...
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
INTRODUCTION: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein ...
Сохранить в:
| Опубликовано в: : | Adv Ther |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Healthcare
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8279985/ https://ncbi.nlm.nih.gov/pubmed/34105088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01796-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|